Healthcare / BiotechnologyAmsterdam
$1.12
-0.03 (-2.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$793M
P/E
56.2x
↑EV/EBITDA
23.3x
↑ROE
1.0%
↑Gross Margin
87.9%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.3%
FCF CAGR
+38.1%
FCF margin
14.3%
FCF / Net income
18.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $376.1M · net income $2.9M · FCF $54.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $376.1M | $376.1M | $297.2M | $245.3M | $205.6M |
| Net Income | $2.9M | $2.9M | $-11.8M | $-10.5M | $13.7M |
| EBITDA | $34.8M | $34.8M | $16.3M | $9.9M | $33.5M |
| EPS | 0.00 | 0.00 | -0.02 | -0.01 | 0.02 |
| Gross Margin | 87.9% | 87.9% | 88.1% | 89.7% | 91.5% |
| Operating Margin | 5.6% | 5.6% | -1.2% | -9.1% | 4.8% |
| Net Margin | 0.8% | 0.8% | -4.0% | -4.3% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.51 | 0.78 | 0.81 |
| Current Ratio | 2.63 | 2.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $54.0M | $54.0M | $-2.6M | $-18.8M | $20.5M |
| Returns | |||||
| ROE | 1.0% | 1.0% | -5.4% | -4.8% | 6.7% |
| Valuation | |||||
| P/E | 56.17 | 56.17 | — | — | 59.37 |
| EV/EBITDA | 23.28 | 23.28 | 47.35 | 83.93 | 23.00 |
| P/B | 3.03 | 3.03 | 3.23 | 3.29 | 3.97 |
| Growth & Yield | |||||
| Revenue Growth | 26.6% | 26.6% | 21.1% | 19.3% | — |
| EPS Growth | 122.2% | 122.2% | -20.0% | -178.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
192.1%
EPS terminal req.
$0.10
Spread vs growth
-69.9%
5Y implied EPS CAGR
97.6%
EPS terminal req.
$0.12
Spread vs growth
24.6%
10Y implied EPS CAGR
47.4%
EPS terminal req.
$0.19
Spread vs growth
74.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → 0.00
Residual
+6.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.